Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He should have been working on that a long time ago
The CEO really dropped the ball here. He should have sold the properties earlier and worked out short term financing sooner. What a debacle. Way to destroy the share structure in three short weeks
Why is the Stock Promotion Warning still up on the OTC site? I dont get it. I thought it would be down by now
https://www.otcmarkets.com/stock/RMSL/overview
Either that or financing news.
OTCQB stocks seem to dilute more than pink sheet stocks. It doesn't seem to be an advantage from an investors standpoint to invest in an OTCQB stock. The dilution is rampant. It's almost like having that status makes it easier for a company to dilute. I think I will go back to investing in empty shells.
According to their press releases they had sold off two of their Florida properties to help pay down their debt. According to their filings, one of their Delray Florida properties was sold for $3.5 million. I didn't expect their to be this much debt left. I guess I miscalculated.
GRST might break the record for lowest market cap in recorded history. It's ridiculous for the stock to be trading down here.
The dilution just never stops here
They were just flagged for Stock Promotion Thursday night if I am not mistaken. I don't recall seeing it on the OTC site prior to that. That is much more concerning than the Shell Risk designation.
Being flagged for Stock Promotion on the OTC site is a bit concerning. That and they also deem this stock as a Shell Risk. I don't quite understand the potential consequences of being flagged but this stock seems to be on their radar for some reason.
For acquisitions
A/S was raised to 10 Billion Shares
They will probably do a reverse split at the rate this is going. The excuse will be they need it to maintain OTCQB status and they didn't know how much in the way of notes were still left.
I love the chart on this one. And the market cap is sub $200,000. It should run big soon
The most important part is the fact that they sold off two of their Florida properties to significantly pay down the debt. By the way, one of the Florida properties sold for $3.5 million. I am not sure how much the other one sold for. But a significant amount of debt has already been paid off. According to their most recent press release they are working to sell their Canadian property and if they do that would eliminate most of the remaining debt.
Check the chart here. Psar at .0009. Stock price at .0008. Market cap only around $160,000. STTH should run soon.
What exactly is the advantage to being an OTCQX stock? They seem to dilute more than pink sheet stocks. I think I will go back to buying stocks that are shells rather than garbage like this that does nothing but continually dilute.
Yes, like a $20 million acquisition. I bought in a week too early but I will be buying more next week.
Try reading the press release from December. They sold off two Florida properties to significantly pay down debt. And they might sell their Canadian property to eliminate the rest of the debt. The point is, I doubt if there is much debt left
The Company has sold two of its properties in Delray Beach, Florida in 2019, reducing debt significantly and may pursue a sale of its Canadian property to eliminate any remaining debt.
From the 12/24/19 GRST Press Release
Around $40 million in 2019 revenues with much growth anticipated in 2020. Oh and the market cap is only around $3 million. KWBT is a no brainer at this level
They are doing $40 million in revenues and the market cap is only $3 million. Some company should buy them out. The share price is undervalued and doesn't make sense. The company should be trading more than 10x higher than it is.
CSTI playing games.
I doubt if he can vote down the reverse split himself. That filing was based on the outstanding share count a month ago. The outstanding share count has tripled since then
The outstanding share count has tripled since December 13th. He owned 48% based on 43 million shares outstanding as of December 13th. As of yesterday there were 119 million shares outstanding. So now he only owns around 20% of the outstanding shares. The sad thing is the outstanding share count for BRTX has tripled in less than a month. The dilution here is ridiculous. Hopefully they will so something to stem the tide here soon
The Ibox should have been left the way it was. With clinical trial information and news. The information in the ibox is wrong imo. He purchased around $800,000 worth of stock total by my calculation. Not $2 million. He purchased over 15 million shares so that is impressive nevertheless.
Maybe Dale should do a hostile takeover of this company and bring in management who could get the valuation up where it belongs?
Disc Repair - BRTX-100
Other groups are putting their focus on degenerative disc disease, a common condition that can lead to near-constant and debilitating pain (5), and specifically on using cell therapy to rebuild the intervertebral disc material (nucleus pulposus) that serves as a shock absorber between the individual vertebra.
One of the companies with significant research in this area is BioRestorative Therapies of Melville, New York, which is growing and expanding stem cells from the patient’s bone marrow, but doing so under hypoxic conditions that mimic those in the normal intervertebral space (6). “So basically we are enriching the cells to be able to survive in this harsh environment,” said Francisco Silva, the company’s chief scientist and vice president of research and development (Figure 3). The researchers combine the cells with platelet lysate, a blood component that is rich in growth factors and nutrients for the cells, and cryopreserve the final cell product, which they call BRTX-100.
“Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution, and that’s it,” he described. The stem cells function in a couple of different ways. “Stem cells by nature are anti-inflammatory (and) release factors to block the inflammation process,” he explained. The company’s initial animal study showed increased disc height following treatment (Figure 4). Another animal study is planned to examine BRTX-100’s mechanism of action, and to measure changes in pain level following treatment.
The FDA authorized BioRestorative Therapies to initiate a phase 2 clinical trial of the BRTX-100 cell product, which will provide for the study of 99 patients.
Figure 3. Francisco Silva, chief scientist and vice president of research and development for BioRestorative Therapies of Melville, New York, which is developing a cell-therapy product called BRTX-100 to rebuild intervertebral disc material
Figure 4. Silva examines a rabbit disc treated with BRTX-100 (inset). The company’s initial animal study demonstrated increased disc height following treatment. Images courtesy of BioRestorative Therapies.
Besides the BRTX-100 cell product, the company is also pursuing an additional cell-therapy project: utilizing brown adipose (fat) derived stem cells for therapeutic purposes. Since brown adipose tissue expends energy (as opposed to white adipose tissue, which stores it), the company’s goal is to develop an implantable brown adipose tissue construct, which it hopes to use for the treatment of metabolic diseases and disorders, such as type 2 diabetes, obesity and hypertension. The company is working in collaboration with the University of Pennsylvania to research brown adipose biology and its role in metabolic disorders and has also retained the University of Utah to provide research services for this program.
https://pulse.embs.org/november-2019/stem-cell-therapies-low-back-pain/
BRTX
BRTX market cap is only around $1.5 million. It's crazy cheap for a company about to embark on a Phase II study.
The Ibox should be changed. The information in there is wrong. He didn't invest that much. Your numbers are way off
We submitted an IND application to the FDA to obtain authorization to commence a Phase 2 clinical trial investigating the use of BRTX-100 in the treatment of chronic lower back pain arising from degenerative disc disease. We have received such authorization from the FDA. We intend to commence such clinical trial during the first quarter of 2020
We develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs are: -- Disc/Spine Program (brtxDISCTM): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous cultured mesenchymal stem cells collected from bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs.
-- Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Disc Repair - BRTX-100
Other groups are putting their focus on degenerative disc disease, a common condition that can lead to near-constant and debilitating pain (5), and specifically on using cell therapy to rebuild the intervertebral disc material (nucleus pulposus) that serves as a shock absorber between the individual vertebra.
One of the companies with significant research in this area is BioRestorative Therapies of Melville, New York, which is growing and expanding stem cells from the patient’s bone marrow, but doing so under hypoxic conditions that mimic those in the normal intervertebral space (6). “So basically we are enriching the cells to be able to survive in this harsh environment,” said Francisco Silva, the company’s chief scientist and vice president of research and development (Figure 3). The researchers combine the cells with platelet lysate, a blood component that is rich in growth factors and nutrients for the cells, and cryopreserve the final cell product, which they call BRTX-100.
“Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution, and that’s it,” he described. The stem cells function in a couple of different ways. “Stem cells by nature are anti-inflammatory (and) release factors to block the inflammation process,” he explained. The company’s initial animal study showed increased disc height following treatment (Figure 4). Another animal study is planned to examine BRTX-100’s mechanism of action, and to measure changes in pain level following treatment.
The FDA authorized BioRestorative Therapies to initiate a phase 2 clinical trial of the BRTX-100 cell product, which will provide for the study of 99 patients.
Figure 3. Francisco Silva, chief scientist and vice president of research and development for BioRestorative Therapies of Melville, New York, which is developing a cell-therapy product called BRTX-100 to rebuild intervertebral disc material
Figure 4. Silva examines a rabbit disc treated with BRTX-100 (inset). The company’s initial animal study demonstrated increased disc height following treatment. Images courtesy of BioRestorative Therapies.
Besides the BRTX-100 cell product, the company is also pursuing an additional cell-therapy project: utilizing brown adipose (fat) derived stem cells for therapeutic purposes. Since brown adipose tissue expends energy (as opposed to white adipose tissue, which stores it), the company’s goal is to develop an implantable brown adipose tissue construct, which it hopes to use for the treatment of metabolic diseases and disorders, such as type 2 diabetes, obesity and hypertension. The company is working in collaboration with the University of Pennsylvania to research brown adipose biology and its role in metabolic disorders and has also retained the University of Utah to provide research services for this program.
https://pulse.embs.org/november-2019/stem-cell-therapies-low-back-pain/
BRTX
BRTX should be announcing a Phase II Trial for their Stem Cell product BRXT-100 to treat chronic lower back pain due to degenerative disk disease any time now. The Phase II trial was already approved by the FDA. That would be a huge market for them to tap into.
Not only that but data from their Metabolic Study could be announced anytime as well. They are using brown adipose derived stem cells (BAT) to target obesity and diabetes. They are working with the University of Pennsylvania and the University of Utah on this project. Obviously obesity and diabetes are another huge market.
The market cap here after yesterday's run is only $1.2 million. Very undervalued for a cutting edge Biotech stock in this stage of development.
Below is a great article highlighting their work in these two areas. They are featured mid way through the article under Disc Repair: BRTX 100
https://pulse.embs.org/november-2019/stem-cell-therapies-low-back-pain/
I wonder what is going on here. The share structure is great for a trip zero stock.
Others pumped it much more than he ever did.
What a pathetic stock this turned out to be.
Seven hundred thousand on the bid. At least some one appears interested in this stock. Unless its a prop bid
This stock is a dog. Nothing has been going on here and nothing is going on now.
So much for this being a good stock. So many shares piled on at .0002 combined with no volume or investor interest makes this stock a total loser